Providers

Latest News

ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
ESA Treatment Improves OS in Lower-Risk MDS

March 28th 2025

Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.

Healthcare concept of professional psychologist doctor consult in psychotherapy session or counsel diagnosis health - Khunatorn - stock.adobe.com
Collaborative Care Approaches Ranked by Depression Outcomes in Primary Care

March 28th 2025

Krazati packaging | Image credit: Mirati Therapeutics
Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-line Treatment of KRAS-mutated NSCLC

March 28th 2025

AMGA logo | Image Credit: © Maggie L. Shaw
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication

March 28th 2025

All 11 participants in the trial have advanced to the extension portion of the study and are receiving WVE-N531 monthly. | Image credit: OlegKachura - stock.adobe.com
WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD

March 27th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo